SCHEMBL3402978

SCHEMBL3402978

COc1cccc(CCC(=O)O)c1OC1CCCC1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRA P10827 2/20 0.48
THRB P10828 2/20 0.48
KMT2A Q03164 1/20 0.45
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
POLB P06746 1/20 0.43
CTSG P08311 1/20 0.43
CMA1 P23946 1/20 0.43
TRPV3 Q8NET8 1/20 0.42
PTGDR Q13258 2/20 0.42
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3407610 0.93 THRA (0.43) THRATHRBKMT2APDE4APDE4B
SCHEMBL3407137 0.88 THRA (0.46) THRATHRBKMT2APDE4APDE4B
SCHEMBL3401123 0.87 KMT2A (0.47) THRATHRBKMT2APDE4APDE4B
SCHEMBL3410076 0.84 PTGER4 (0.55) THRATHRBPTGDRPTGER1PTGER4
SCHEMBL490691 0.82 CTSG (0.56) KMT2ACTSGCMA1PTGER1PTGER4
SCHEMBL27926791 0.82 PTGDR (0.58) THRATHRBPDE4APDE4BPDE4C
SCHEMBL27908885 0.82 THRA (0.50) THRATHRBPTGDRPTGER1PTGER4
SCHEMBL7360412 0.81 TAAR1 (0.53) KMT2A
SCHEMBL3405256 0.81 THRA (0.56) THRATHRBPOLBPTGDRPTGER1
SCHEMBL7885276 0.81 CTSG (0.55) KMT2ACTSGCMA1PTGER1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 US disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
EP-2254879-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2010-12-01 EP disclosed
WO-2009084034-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS TRPV3, TRPV2, TRPV1 THRA 530/4885THRB 662/4885KMT2A 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.